Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe

International Journal of Cancer

Volumn 109, Issue 5, 2004, Pages 721-727

  Stahlberg, Claudia ^a,c   Pedersen, Anette Tønnes ^a   Lynge, Elsebeth ^a   Andersen, Zorana Jovanovic ^a   Keiding, Niels ^a   Hundrup, Yrsa Andersen ^b   Obel, Erik B ^b   Ottesen, Bent ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NONE   (Denmark)

Author keywords

Breast cancer; Breast neoplasm; Epidemiology; Estradiol; Estrogens; Hormone replacement therapy; Menopause; Progestin; Sex steroids

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; SEX HORMONE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; DRUG EFFECT; EUROPE; FEMALE; FREQUENCY ANALYSIS; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIFESTYLE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; SUBSTITUTION THERAPY;

AGED; BREAST NEOPLASMS; COHORT STUDIES; CONFIDENCE INTERVALS; DENMARK; ESTROGENS; EUROPE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; NURSES; ODDS RATIO; PROGESTINS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS;

EID: 1642419529     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20016     Document Type: Article

References (27)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 1997:350:1047-59.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II). JAMA 2002;288:58-66.
4. Beral V. Breast cancer and hormone-replacement therapy in the Million Women's Study. Lancet 2003;362:419-27.
5. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relafion to breast cancer. JAMA 2002;287:734-41.
6. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestr. Int J Cancer 1999;81:339-44.
7. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
8. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847-54.
9. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100:1148-58.
10. Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 2003;82:335-44.
11. Hundrup YA, Obel EB, Rasmussen NK, Philip J. Use of hormone replacement therapy among Danish nurses in 1993. Acta Obstet Gynecol Scand 2000;79:194-201.
12. Loekkegaard E, Johnsen SP, Heitmann B, Stahlberg C, Pedersen AT, Obel EB, Hundrup YA, Hallas J, Sørensen HT. The validity of self-reported use of hormone replacement therapy among Danish nurses. Acta Obstet Gynecol Scan, in press.
13. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry: a study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002;11:359-64.
14. Rostgaard K, Holst H, Mouridsen HT, Lynge E. Do clinical databases render population-based cancer registers obsolete? the example of breast cancer in Denmark. Cancer Causes Control 2000;11:669-74.
15. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997;72:758-76.
16. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
18. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
19. Magnusson C, Persson I, Adami HO. More about: effect of hormone replacement therapy on breast cancer risk - estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:1183-4.
20. Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopausal hormones and breast cancer in a biracial population. Am J Pub Health 2000;90:966-71.
21. Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, Russo IH. 17beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002;80:149-62.
22. Kuller LH. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:1100-1.
23. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998;147:718-21.
24. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
25. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9.
26. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
27. Sendag F, Cosan TM, Ozsener S, Oztekin K, Bilgin O, Bilgen I, Memis, A. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50.